State and federal investigators claimed McKesson inflated prices by as much as 25 percent for 1,400 brand-name drugs from 2001 to 2009. This allegedly caused Medicaid programs to pay millions of dollars more in reimbursements.
The drugmaker has denied wrongdoing. A McKesson spokesperson said the claims were without merit but determined a settlement was in the best interest of company employees, customers, suppliers and shareholders, according to the report.
More Articles on Pharmaceutical Companies and Settlements:
Largest Healthcare Settlement in U.S. History: GlaxoSmithKline to Pay $3B
J&J to Pay $2.2B Settlement to End Risperdal Probes
Abbott to Pay $1.5B Settlement for Off-Label Marketing of Depakote
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
